HP-hMG has shown clinical superiority over rFSH for ovarian stimulation in IVF/ICSI cycles based on meta-analyses evidence. Studies in the 2000s found no significant difference in clinical pregnancy rates between hMG and rFSH, but when accounting for the fact that over 2/3 of hMG patients used HP-hMG, meta-analyses revealed higher clinical pregnancy and live birth rates with HP-hMG compared to rFSH. Due to better live birth outcomes, HP-hMG is now preferred over rFSH for ovarian stimulation in IVF cycles.